ATI LPN
Pharmacology and the Nursing Process 10th Edition Test Bank
Chapter 20 : Cholinergic Drugs Questions
Question 1 of 5
When monitoring a patient who is taking a cholinergic drug, the nurse will watch for which cardiovascular effect?
Correct Answer: A
Rationale: The cardiovascular effects of cholinergic drugs are decreased heart rate (bradycardia) and vasodilation. Palpitations and tachycardia are not effects of cholinergic drugs, and vasoconstriction is opposite to the vasodilation caused by these drugs.
Question 2 of 5
The nurse notes in a patient's medication history that the patient is taking pilocarpine. Based on this finding, the nurse interprets that the patient has which disorder?
Correct Answer: B
Rationale: Pilocarpine is a direct-acting cholinergic drug used topically to reduce intraocular pressure in patients with glaucoma. The other disorders are not indications for pilocarpine.
Question 3 of 5
A patient has had an overdose of an intravenous cholinergic drug. The nurse expects to administer which drug as an antidote?
Correct Answer: D
Rationale: Prompt administration of atropine sulfate can reverse a toxic dose of cholinergic drugs by blocking muscarinic receptors. The other drugs listed are not antidotes to cholinergic toxicity.
Question 4 of 5
A patient who has had abdominal surgery has been discharged on a cholinergic drug to assist in increasing gastrointestinal peristalsis. The nurse will teach this patient to look for which therapeutic effect?
Correct Answer: C
Rationale: In patients with decreased GI peristalsis postoperatively, a cholinergic drug should result in increased bowel sounds, passage of flatus, and bowel movements, indicating enhanced GI peristalsis. The other options are not the primary therapeutic effects.
Question 5 of 5
A cholinergic drug is prescribed for a patient with a new diagnosis of myasthenia gravis, and the nurse provides instructions to the patient about the medication. What is important to include in the teaching?
Correct Answer: C
Rationale: Taking the medication 30 minutes before meals allows time for the onset of action and therapeutic effects during the meal, improving swallowing and chewing in myasthenia gravis. Doses should be spaced evenly, and taking with meals may not prevent GI distress. Taking only when difficulty swallowing occurs is incorrect.